Quick Answer
Cyclerion Therapeutics, Inc. reported Diluted EPS of $1.11 per share (loss) for fiscal year 2025.
Cyclerion Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.11 | +8.3% |
| 2024 | -$1.21 | +46.2% |
| 2023 | -$2.25 | +88.9% |
| 2022 | -$20.28 | -1436.4% |
| 2021 | -$1.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.30 | -3.4% | -172.7% |
| June 30, 2025 | -$0.11 | +79.2% | +80.4% |
| March 31, 2025 | -$0.56 | +9.7% | -93.1% |
| September 30, 2024 | -$0.29 | -110.7% | +45.3% |
| June 30, 2024 | -$0.53 | +71.0% | +14.5% |
| March 31, 2024 | -$0.62 | +80.6% | -122.8% |
| September 30, 2023 | $2.72 | +156.3% | +248.6% |
| June 30, 2023 | -$1.83 | +70.3% | +42.8% |
- Cyclerion Therapeutics, Inc. showed an increase of +8.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Cyclerion Therapeutics, Inc.’s diluted eps has grown by 15.9% (from $1.32 per share (loss) to $1.11 per share (loss)).
- The most recent figure is from Cyclerion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: